Although these therapies have the potential of reducing the risk of heart attack and stroke for millions of people with high cholesterol, they come at significant cost to employers and the health care system. The good news is the only patients that should take PCSK9s are those who have failed statin therapy or have a genetic mutation; greatly reducing the number of patients who need them. In fact, in order for a patient to gain access to one of the two new FDA approved PCSK9s, they need to have a documented diagnosis in order to receive reimbursement.
Want to know more? CBGH members are invited to join the National Business Coalition on Health for a webcast offering up-to-date information about PCSK9 inhibitors.
PCSK9: What Health Care Purchasers Need to Know
Wednesday, October 14
2:00-3:30 PM ET